Novo Nordisk said that patients taking a pill form of Wegovy in a clinical trial lost about as much weight as those who get ...

Makers of GLP-1 drugs, including Novo Nordisk, Eli Lilly and others, are close to releasing daily pills to help shed pounds ...

Eli Lilly's bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, and ...

Late Tuesday and early Wednesday, Eli Lilly reported more data on orforglipron, which together don’t seem strengthen the case ...

Eli Lilly said that it will apply for regulatory approval for the weight-loss pill in multiple markets around the world ...

Eli Lilly's new oral pill, orforglipron, shows promising results. Trials reveal it is more effective than existing oral ...

The drug. orforglipron, works on the same receptor as semaglutide (Ozempic/Wegovy), but can be taken without restrictions on food or water intake.

Novo hopes that because the Wegovy pill has the same active ingredient as the injectable version, regulators and doctors will recognise the broader health benefits of both. Previous trials have found ...

A new type of weight loss jab can help maintain weight reductions by tackling the underlying causes of obesity, scientists ...

An IQVIA report published earlier this year found that 43% of anti-obesity assets currently in development are orally ...

Obesity is one of the most stubborn health challenges of our time, linked with diabetes, heart disease, sleep problems, and shortened lifespans. Doctors have long sought treatments that not only help ...

On 5Live, the focus is on a new daily pill from Eli Lilly that could aid significant weight loss, potentially replacing injectables like Ozempic. In a phase three trial, over 3,000 overweight or obese ...